San Francisco, CA. March 10, 2022 — The Vial Dermatology CRO announced the addition of Dr. David Pariser, MD to the Vial Scientific Advisory Board. Dr. Pariser is currently the Senior Physician at Pariser Dermatology Specialists. Dr. Pariser will share his knowledge and insights from his 40+ years as a practicing Dermatologist to the Vial CRO team and Dermatology sponsors.
Launched earlier this year, under the tag line, “The CRO Built for Sponsors”, the Vial Dermatology CRO promises higher quality and faster execution of trials powered by the Vial Clinic Network of over 35 Dermatology clinical research sites across the country. The Vial Scientific Advisory Board’s leading Dermatology KOLs will service sponsors in clinical strategy, regulatory strategy, trial design and indication selection.
The Vial Dermatology CRO team is led by Betsey Zbyszynski as Head of Clinical Operations, Jason Shuris as Head of Sales, Janet DuBois, M.D. as Medical Director, and Justin Withers as Head of Dermatology. Together, the CRO executive team brings 100+ years of combined dermatology clinical trial experience to Vial.
Dr. Pariser stated: “I am excited to support the Vial team, along with their sponsors, as they utilize technology to advance the field of Dermatology research.”
Dr. Pariser is board-certified by the American Board of Dermatology and the American Board of Pathology with a special competence in Dermatopathology. Dr. Pariser is distinguished for his world-renowned expertise on psoriasis, hyperhidrosis and photodynamic therapy, a treatment for early skin cancers and pre-cancers. Throughout the span of his career, his research has led to the publication of over 300 scientific publications and 4 textbooks in medical literature.
In 2009, Dr. Pariser was elected as the President of the American Academy of Dermatology. In addition, he was honored with the title “Educator of the Year” by the Fall and Winter Clinical Dermatology Conferences. Dr. Pariser is also a member of the Executive Committee of the International League of Dermatologic Societies, the world body of dermatology. In this position, he has travelled to Tanzania on several occasions to provide patient care and dermatology education to seriously under-served populations in sub-Saharan Africa.
Vial’s mission is to run clinical trials with faster execution and higher quality in order to bring new therapies to market. Vial has over 70 employees and is based in San Francisco, California. Vial partners with Dermatologists to support their research teams and has created a network of over 35 Dermatology clinics. The Vial network has contributed to over 150 trials for many of the leading sponsors in Dermatology having run trials across common Dermatology indications (Atopic Dermatitis, Psoriasis, Vitiligo, Alopecia Areata, Rosacea, Hidradenitis Suppurativa, Prurigo Nodularis among others) as well as many Aesthetic Dermatology indications. The clinic network runs trials from Phase I through Phase IV.